CAP256V2LS

N/A

Report date: 2024/06/27 14:54:23

Base Information

Drug NameCAP256V2LS
Drug Alias NameVRC-HIVMAB0102-00-ABCAP256V2S
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionEnvelope glycoprotein gp160 inhibitors
TargetsEnvelope glycoprotein gp160
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)The Centre For The Aids Programme Of Research In South Africa (Caprisa)
China Registration ClassN/A

Develop Information

Active CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A